"They look at us like junkies": influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City.

Muncan B, Walters SM, Ezell J, Ompad DC. · 2020

Read "They look at us like junkies": influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. by Muncan B, Walters SM, Ezell J, Ompad DC. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7393740.txt.

Introduction

Muncan and co-authors interview people who inject drugs in New York City about stigma in health care, in Harm Reduction Journal. This group faces high rates of overdose, mental illness, and infections such as HIV and hepatitis C. The team ran semi-structured interviews with 32 participants and coded the transcripts for themes.

About 78 percent reported at least one stigmatizing experience in medical settings, and 71.9 percent described enacted stigma, being treated as junkies by staff. Many expected such treatment before walking in. Syringe service programs stood out in the opposite way, with 62.5 percent reporting positive experiences there. Stigma, the authors conclude, pushes people away from care they need, deepening the very disparities services aim to close.

Catalog record

CREATORMuncan B, Walters SM, Ezell J, Ompad DC.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7393740

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

“They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City By Brandon Muncan, Suzan M. Walters, Jerel Ezell, Danielle C. Ompad Published in: Harm Reduction Journal DOI: 10.1186/s12954-020-00399-8 ABSTRACT Background People who inject drugs (PWID) are a medically and socially vulnerable population with a high incidence of overdose, mental illness, and infections like HIV and hepatitis C. Existing literature describes social and economic correlations to increased health risk, including stigma. Injection drug use stigma has been identified as a major contributor to healthcare disparities for PWID. However, data on this topic, particularly in terms of the interface between enacted, anticipated, and internalized stigma, is still limited. To fill this gap, we examined perspectives from PWID whose stigmatizing experiences impacted their views of the healthcare system and syringe service programs (SSPs) and influenced their decisions regarding future medical care. Methods Semi-structured interviews conducted with 32 self-identified PWID in New York City. Interviews were audio recorded and transcribed. Interview transcripts were coded using a grounded theory approach by three trained coders and key themes were identified as they emerged. Results A total of 25 participants (78.1%) reported at least one instance of stigma related to healthcare system engagement. Twenty-three participants (71.9%) reported some form of enacted stigma with healthcare, 19 participants (59.4%) described anticipated stigma with healthcare, and 20 participants (62.5%) reported positive experiences at SSPs. Participants attributed healthcare stigma to their drug injection use status and overwhelmingly felt distrustful of, and frustrated with, medical providers and other healthcare staff at hospitals and local clinics. PWID did not report internalized stigma, in part due to the availability of non-stigmatizing medical care at SSPs. Conclusions Stigmatizing experiences of PWID in formal healthcare settings contributed to negative attitudes toward seeking healthcare in the future. Many participants describe SSPs as accessible sites to receive high-quality medical care, which may curb the manifestation of internalized stigma derived from negative experiences in the broader healthcare system. Our findings align with those reported in the literature and reveal the potentially important role of SSPs. With the goal of limiting stigmatizing interactions and their consequences on PWID health, we recommend that future research include explorations of mechanisms by which PWID make decisions in stigmatizing healthcare settings, as well as improving medical care availability at SSPs. BACKGROUND People who inject drugs (PWID) have a higher risk of morbidity and mortality from overdose, mental illness, and transmissible infections such as HIV and hepatitis C (HCV), soft tissue infections, and endocarditis [1–5]. The higher risk among PWID compared to the general population is oftentimes attributable to poor healthcare engagement resulting from socioeconomic and structural barriers directly related to drug use or its consequences (i.e., discrimination, criminalization, unstable housing, and inability to afford care [2, 6]). From a public health standpoint, it is imperative to consider the experiences of PWID so that systemic changes can be implemented to improve the health of this medically and socially vulnerable population. Existing literature has revealed that social stigma strongly influences PWIDs’ healthcare system engagement. The concept of stigma was formulated by Goffman in his pioneering book, Stigma: Notes on the Management of Spoiled Identity [7]. For Goffman, stigma was an attribute, behavior, or reputation that placed a person outside of societal norms. This alienation, which carried a negative connotation, discredited the person with the negative attribute, making society view them as less desirable. In effect, the person became marked with a “spoiled identity” [7]. Later research expanded the stigma construct beyond the individual and interpersonal levels to consider broader, macrosocial forms of stigma including structural stigma—which includes the systematic devaluation of certain identities within institutional settings such as hospitals [8, 9]. Some posited that structural stigma included institutional policies that either intentionally restricted the opportunities of, or yield unintended consequences for, certain individuals [10]; others focused on how dominant cultural norms dictated whether certain identities or statuses were socially devalued, such as the punitive responses to maternal substance use during pregnancy [11]. Of theoretical importance, Earnshaw and Chaudoir describe stigma mechanisms as related to HIV; they conclude that the interplay between enacted, anticipated, and internalized stigma influences mental and physical health outcomes [12]. Enacted stigma, as adapted from HIV to a drug use paradigm, is defined as experiences of discrimination or prejudice related to drug use felt by people who use drugs (PWUD); anticipated stigma is the expectation of future discrimination or prejudice, and internalized stigma is the acceptance of negative views and self-devaluation as a result of drug use [12]. These stigma mechanisms are of particular public health importance when experienced by PWID in healthcare settings. Research shows that drug use stigma, and discrimination as a result of drug use stigma, adversely impacts mental and physical health [13, 14]. Compared to other forms of social stigma, stigma against drug use has been found to be greater than that against smoking, obesity, and mental illness [1, 15]. Furthermore, some drugs and drug use behaviors are more stigmatized than others, thus contributing to a hierarchy by drug type [13]. Overall, compared to non-injectors, people who inject drugs may experience higher rates of drug use and other forms of social stigma [16]. Lastly, it is important to note that several authors have independently found correlations between stigma and dangerous health behaviors, specifically demonstrating that drug use stigma is associated with increased syringe and injection equipment sharing as well as risky sexual behaviors [17–19]. These studies illustrate the importance of understanding stigma related to injection drug use, as drug use stigma impacts individuals’ behaviors, and those behaviors can increase risks for disease. Framed within Earnshaw and Chaudoir’s three stigma mechanisms [12], we aimed to qualitatively assess PWIDs experiences with drug use stigma in healthcare and harm reduction settings. METHODS Sample We partnered with a New York City (NYC) syringe services program (SSP) that offered a comprehensive set of services including syringe exchange, safer sex supplies, pipes for smoking drugs such as crack cocaine and/or methamphetamines, HIV and HCV testing, on-site HCV treatment, opioid overdose prevention services, medical and mental healthcare counseling and referrals, case management services, various peer groups, computer and internet access, phones, and food. Self-identified PWID that used the SSP were recruited to participate in one of two studies focusing on HIV prevention. One study recruited PWID whose drugs of choice were opioids and the other recruited PWID whose drugs of choice were amphetamines. Study staff spent 1 day per week at the SSP learning about the community, building rapport with participants and staff, and conducting interviews. A total of 32 PWID, age ≥ 18 who injected drugs within the past year were identified in collaboration with the SSP staff to ensure recent injection drug use status. Informed consent was obtained from all participants. Once identified, study staff would recruit individuals for a semi-structured interview for either the opioid or amphetamine study, depending on their drug of choice. After each interview, the study staff immediately created a memo describing their observations and experiences [20]. Each participant received $40 for participating. All protocols were approved by the institutional review board at New York University. Interview structure The 32 semi-structured interviews were conducted from August

Read the complete text